Abstract: The present invention relates to a gas supply pump comprising: a camshaft which can be rotated; a plurality of cam noses provided at regular intervals in a lengthwise direction of the camshaft and having an eccentric shape from the center of the camshaft; a cam roller provided to be in close contact with each cam nose; and a drive shaft and a piston provided to neighbor with one side of the cam roller; and a liquefied gas compression device which pressurizes and exhausts a liquefied gas according to a straight reciprocation of the piston.

Abstract: An embodiment power control apparatus for a fuel cell vehicle includes a first relay connected to a fuel cell stack, a second relay selectively connected to an external charger, a converter connected to the first relay and the second relay, wherein the converter is configured to convert first electric power input thereto via the first relay into first demand electric power, convert second electric power input thereto via the second relay into second demand electric power, and supply the first demand electric power or the second demand electric power to a power consumption device, and a controller configured to control the first relay, the second relay, and the converter.

Abstract: The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

Abstract: The present invention relates to a CD5 antibody and a chimeric antigen receptor (CAR) including the same. The chimeric antigen receptor of the present invention may be expressed in an immune cell to be utilized for an immuno-oncology therapy having reduced toxicity against a normal T cell.

Abstract: Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

Abstract: The present invention relates to an mRNA construct, comprising a target protein or peptide coding region and an IRES region downstream of the target protein or peptide coding region, wherein the mRNA construct of the present invention can stably maintain the expression of a target protein for a long time while being stably present in the cell.

Abstract: Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.